Elinzanetant (developmental code names BAY-3427080 GSK-1144814, NT-814) is an orally active small-molecule neurokinin/tachykinin NK1 receptor and NK3 receptor antagonist which is under development by Bayer, GlaxoSmithKline, and NeRRe Therapeutics for the treatment of hot flashes and "sex hormone disorders".[1][2] It has been found to relieve hot flashes in postmenopausal women and to dose-dependently suppress luteinizing hormone, estradiol, and progesterone levels in premenopausal women.[2][3] As of August 2021, elinzanetant is in phase 2 clinical trials for hot flashes and "sex hormone disorders".[1] It was also under development for the treatment of schizophrenia and opioid-related disorders, but development was discontinued for these uses.[1]
See also
References
- ^ a b c "Elinzanetant - Bayer". Adis Insight. Springer Nature Switzerland AG.
- ^ a b Depypere H, Lademacher C, Siddiqui E, Fraser GL (July 2021). "Fezolinetant in the treatment of vasomotor symptoms associated with menopause". Expert Opinion on Investigational Drugs. 30 (7): 681–694. doi:10.1080/13543784.2021.1893305. hdl:1854/LU-8758954. PMID 33724119.
- ^ Pawsey S, Mills EG, Ballantyne E, Donaldson K, Kerr M, Trower M, Dhillo WS (July 2021). "Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women". The Journal of Clinical Endocrinology and Metabolism. 106 (8): e3221–e3234. doi:10.1210/clinem/dgab108. PMC 8277204. PMID 33624806.
Recent Comments